This six-month study is evaluating the patient satisfaction and physician assessment when a change is made from Previous Disease Modifying Therapy (DMT) to Fingolimod (Gilenya) without a washout period.

Major Inclusion/Exclusion

• Ages 18-65 yrs.
• Patients must have Relapsing Remitting or Secondary Progressive MS
• Must have been on a DMT continuously for at least the last six months